GLI1 activation is a key mechanism of erlotinib resistance in human non‑small cell lung cancer

Lung cancer is the leading cause of cancer-associated death worldwide. In recent years, the advancement of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) targeted therapies has provided clinical benefits for lung cancer patients with EGFR mutations. The response to EGFR-TKI va...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Oncology letters 2020-10, Vol.20 (4), p.1-76
Hauptverfasser:	Dong, Zhouhuan, Wang, Yun, Ding, Vivianne, Yan, Xiang, Lv, Yali, Zhong, Mei, Zhu, Fengwei, Zhao, Po, He, Charlotte, Ding, Feng, Shi, Huaiyin
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic agents Cancer research Cancer therapies Cell growth Chemotherapy Drug resistance Epidermal growth factors FDA approval Gene expression Growth factors Health aspects Immunohistochemistry Inhibitor drugs Kinases Lung cancer Mutation Non-small cell lung cancer Oncology Osimertinib Patients Proteins Scientific equipment industry Signal transduction Small cell lung cancer Targeted cancer therapy Transcription factors Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!